Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Clinical and pathological data for patients with prostate tissue samples
- Status
- Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation.
The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.
Investigators
Kara Maxwell
Principal investigator
Abramson Cancer Center at Penn Medicine
Eligibility Criteria
Inclusion Criteria
- •Carriers (Group 1):
- •Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.
- •Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
- •Controls (Group 2):
- •1\. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Clinical and pathological data for patients with prostate tissue samples
Time Frame: 5 years
Data will be collected on consented patients who undergo prostate biopsy, prostatectomy or metastatic biopsy.